Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 17.77% is 315% above its 5-year average of -8.28%, near the high end of its 5-year range (-61.61%–17.77%).
As of the fiscal period ended Tuesday, June 30, 2026. 199.81% above its 12-month average of -17.80%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): 17.77%.
RETURN ON EQUITY (ROE)
17.77%
RETURN ON EQUITY (ROE) AVG TTM
-17.80%
RETURN ON EQUITY (ROE) AVG 3Y
-17.80%
RETURN ON EQUITY (ROE) AVG 5Y
-8.28%
RETURN ON EQUITY (ROE) AVG 10Y
6.85%
RETURN ON EQUITY (ROE) AVG 15Y
10.87%
RETURN ON EQUITY (ROE) AVG 20Y
11.66%
CURRENT VS TTM AVG
+199.81%
CURRENT VS 3Y AVG
+199.81%
CURRENT VS 5Y AVG
+314.56%
CURRENT VS 10Y AVG
+159.38%
CURRENT VS 15Y AVG
+63.46%
CURRENT VS 20Y AVG
+52.34%
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
+142.29%
vs the sector median at left
Caris Life Sciences, Inc.
Market Cap
$7.90B
Return on Equity (ROE)
17.77%
TTM Avg
-17.80%
3Y Avg
-17.80%
5Y Avg
-8.28%
Market Cap
$8.03B
Return on Equity (ROE)
73.08%
TTM Avg
39.77%
3Y Avg
-73.65%
5Y Avg
-82.53%
Market Cap
$7.71B
Return on Equity (ROE)
-25.29%
TTM Avg
-37.79%
3Y Avg
-133.44%
5Y Avg
-103.64%
Market Cap
$7.63B
Return on Equity (ROE)
N/A
TTM Avg
277.25%
3Y Avg
262.80%
5Y Avg
141.77%
Market Cap
$7.62B
Return on Equity (ROE)
11.88%
TTM Avg
7.39%
3Y Avg
4.04%
5Y Avg
2.40%
Market Cap
$7.56B
Return on Equity (ROE)
31.68%
TTM Avg
-71.21%
3Y Avg
-55.91%
5Y Avg
-55.91%
Market Cap
$8.37B
Return on Equity (ROE)
26.84%
TTM Avg
-21.41%
3Y Avg
-36.14%
5Y Avg
-25.75%
Market Cap
$7.34B
Return on Equity (ROE)
-128.44%
TTM Avg
-77.53%
3Y Avg
-74.21%
5Y Avg
-60.06%
Market Cap
$8.62B
Return on Equity (ROE)
-19.85%
TTM Avg
-23.25%
3Y Avg
-28.82%
5Y Avg
-25.53%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Caris Life Sciences, Inc. (CAI) | $7.90B | 17.77% | -17.80% | -17.80% | -8.28% |
| TG Therapeutics, Inc. (TGTX)vs › | $8.03B | 73.08% | 39.77% | -73.65% | -82.53% |
| Praxis Precision Medicines, Inc. (PRAX)vs › | $7.71B | -25.29% | -37.79% | -133.44% | -103.64% |
| Cytokinetics, Incorporated (CYTK)vs › | $7.63B | N/A | 277.25% | 262.80% | 141.77% |
| HealthEquity, Inc. (HQY)vs › | $7.62B | 11.88% | 7.39% | 4.04% | 2.40% |
| Hinge Health, Inc. (HNGE)vs › | $7.56B | 31.68% | -71.21% | -55.91% | -55.91% |
| Oscar Health, Inc. (OSCR)vs › | $8.37B | 26.84% | -21.41% | -36.14% | -25.75% |
| Ionis Pharmaceuticals, Inc. (IONS)vs › | $7.34B | -128.44% | -77.53% | -74.21% | -60.06% |
| Kymera Therapeutics, Inc. (KYMR)vs › | $8.62B | -19.85% | -23.25% | -28.82% | -25.53% |
| Alkermes plc (ALKS)vs › | $7.03B | 3.66% | 19.17% | 13.19% | 6.34% |
ROE
17.8%
ROA
8.6%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | 17.77% |
| 2026-03-31 | 5.73% |
| 2025-12-31 | -11.79% |
| 2025-09-30 | -39.09% |
| 2025-06-30 | -61.61% |
| 2021-09-30 | 17.37% |
| 2021-06-30 | 13.67% |
| 2021-03-31 | 8.92% |
| 2020-12-31 | 3.95% |
| 2020-09-30 | 3.05% |
| 2020-06-30 | 0.17% |
| 2020-03-31 | 1.61% |
| 2019-12-31 | 4.47% |
| 2019-09-30 | 6.21% |
| 2019-06-30 | 9.98% |
| 2019-03-31 | 11.36% |
| 2018-12-31 | 11.21% |
| 2018-09-30 | 13.75% |
| 2018-06-30 | 14.57% |
| 2018-03-31 | 13.48% |
| 2017-12-31 | 12.78% |
| 2017-09-30 | 7.22% |
| 2017-06-30 | 2.71% |
| 2017-03-31 | 0.88% |
| 2016-12-31 | 1.31% |
| 2016-09-30 | -1.54% |
| 2016-06-30 | 2.43% |
| 2016-03-31 | 4.42% |
| 2015-12-31 | 5.83% |
| 2015-09-30 | 11.71% |
| 2015-06-30 | 12.47% |
| 2015-03-31 | 12.97% |
| 2014-12-31 | 13.63% |
| 2014-09-30 | 13.99% |
| 2014-06-30 | 13.84% |
| 2014-03-31 | 14.47% |
| 2013-12-31 | 15.42% |
| 2013-09-30 | 16.53% |
| 2013-06-30 | 17.59% |
| 2013-03-31 | 17.94% |
| 2012-12-31 | 18.30% |
| 2012-09-30 | 21.26% |
| 2012-06-30 | 21.58% |
| 2012-03-31 | 21.09% |
| 2011-12-31 | 21.82% |
| 2011-09-30 | 21.90% |
| 2011-06-30 | 21.09% |
| 2011-03-31 | 19.67% |
| 2010-12-31 | 15.80% |
| 2010-09-30 | 14.26% |
| 2010-06-30 | 11.06% |
| 2010-03-31 | 9.64% |
| 2009-12-31 | 10.50% |
| 2009-09-30 | -26.92% |
| 2009-06-30 | -25.61% |
| 2009-03-31 | -24.15% |
| 2008-12-31 | -23.69% |
| 2008-09-30 | 14.85% |
| 2008-06-30 | 16.07% |
| 2008-03-31 | 15.28% |
| 2007-12-31 | 14.67% |
| 2007-09-30 | 6.40% |
| 2007-06-30 | 6.00% |
| 2007-03-31 | 25.83% |
| 2006-12-31 | 18.93% |
